Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT05147467 is registered in ClinicalTrials.gov with Ascentage Pharma Group Inc. as lead sponsor.

NCT NCT05147467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05147467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Lead sponsor
Ascentage Pharma Group Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
December 28, 2021
Completion date
December 31, 2027
Enrollment
75 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, small lymphocytic lymphoma